

# Mattias Ekstedt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5072296/publications.pdf>

Version: 2024-02-01

77  
papers

9,883  
citations

117625

34  
h-index

69250

77  
g-index

80  
all docs

80  
docs citations

80  
times ranked

9893  
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Diseaseâ€”A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 283-298.	4.4	7
2	Risk for hepatic and extrahepatic outcomes in nonalcoholic fatty liver disease. <i>Journal of Internal Medicine</i> , 2022, 292, 177-189.	6.0	11
3	Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 60-69.	1.5	3
4	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
5	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	4.9	20
6	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. <i>Journal of Hepatology</i> , 2022, 76, 1013-1020.	3.7	66
7	The paradigm shift from <scp>NAFLD</scp> to <scp>MAFLD</scp>: A global primary care viewpoint. <i>Liver International</i> , 2022, 42, 1259-1267.	3.9	15
8	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 1001-1012.	3.7	54
9	Repeated measurements of noninvasive fibrosis tests to monitor the progression of nonalcoholic fatty liver disease: A long-term follow-up study. <i>Liver International</i> , 2022, 42, 1545-1556.	3.9	6
10	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	3.7	114
11	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2008-e2020.	3.6	27
12	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. <i>Hormones</i> , 2022, 21, 349-368.	1.9	12
13	Hepatic patatinlike phospholipase domain-containing 3 levels are increased in 1148M risk allele carriers and correlate with NAFLD in humans. <i>Hepatology Communications</i> , 2022, 6, 2689-2701.	4.3	5
14	â€œConsiderations in the search for under-reported alcohol consumption in NAFLDâ€• <i>Journal of Hepatology</i> , 2022, , .	3.7	2
15	Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154439.	3.4	41
16	Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. <i>JHEP Reports</i> , 2021, 3, 100197.	4.9	41
17	Morbidity, risk of cancer and mortality in 3645 <i>HFE</i> mutations carriers. <i>Liver International</i> , 2021, 41, 545-553.	3.9	11
18	Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 437-442.	1.5	4

#	ARTICLE	IF	CITATIONS
19	A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. <i>Hepatology Communications</i> , 2021, 5, 1021-1035.	4.3	23
20	Reply to: "Rationale of adding muscle volume to muscle fat infiltration in the definition of an adverse muscle composition is unclear". <i>JHEP Reports</i> , 2021, 3, 100257.	4.9	1
21	European "NAFLD Preparedness Index" Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021, 3, 100234.	4.9	27
22	Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. <i>JHEP Reports</i> , 2021, 3, 100218.	4.9	26
23	Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. <i>BMC Gastroenterology</i> , 2021, 21, 180.	2.0	5
24	Low hepatic manganese concentrations in patients with hepatic steatosis – A cohort study of copper, iron and manganese in liver biopsies. <i>Journal of Trace Elements in Medicine and Biology</i> , 2021, 67, 126772.	3.0	15
25	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
26	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020, 72, 14-24.	3.7	123
27	Cardiorespiratory fitness, muscular strength, and obesity in adolescence and later chronic disability due to cardiovascular disease: a cohort study of 1 million men. <i>European Heart Journal</i> , 2020, 41, 1503-1510.	2.2	68
28	Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1592-1599.e8.	4.4	21
29	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	1.8	71
30	Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 848-859.	1.5	15
31	Bariatric surgery versus standard obesity treatment and the risk of severe liver disease: Data from the Swedish Obese Subjects study. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 19, 2675-2676.e2.	4.4	3
32	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	205
33	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154413.	3.4	45
34	Bleeding complications with clopidogrel or ticagrelor in ST-elevation myocardial infarction patients – A real life cohort study of two treatment strategies. <i>IJC Heart and Vasculature</i> , 2020, 27, 100495.	1.1	9
35	Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154183.	3.4	39
36	The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 1069-1078.	3.9	31

#	ARTICLE	IF	CITATIONS
37	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort†. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	3.7	279
38	Modifiers of Liver-Related Manifestation in the Course of NAFLD. <i>Current Pharmaceutical Design</i> , 2020, 26, 1062-1078.	1.9	8
39	Assessing the disease burden of non-alcoholic fatty liver disease in the real world – big data and big numbers. <i>BMC Medicine</i> , 2019, 17, 123.	5.5	4
40	Model-inferred mechanisms of liver function from magnetic resonance imaging data: Validation and variation across a clinically relevant cohort. <i>PLoS Computational Biology</i> , 2019, 15, e1007157.	3.2	6
41	Alcohol consumption in non-alcoholic fatty liver disease – harmful or beneficial?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 311-313.	1.5	3
42	Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1214-1222.	3.7	55
43	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1148-1156.e4.	4.4	71
44	PNPLA3 variant M148 causes resistance to starvation-mediated lipid droplet autophagy in human hepatocytes. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 343-356.	2.6	44
45	Liver R2* is affected by both iron and fat: A dual biopsy-validated study of chronic liver disease. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 325-333.	3.4	22
46	Cardiovascular risk factors in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 197-204.	3.9	75
47	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. <i>Hepatology Communications</i> , 2018, 2, 48-57.	4.3	200
48	Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. <i>Hepatology Communications</i> , 2018, 2, 199-210.	4.3	102
49	Bleeding complications after myocardial infarction in a real world population - An observational retrospective study with a sex perspective. <i>Thrombosis Research</i> , 2018, 167, 156-163.	1.7	6
50	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , 2017, 65, 1557-1565.	7.3	1,294
51	Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis. <i>Gastroenterology</i> , 2017, 153, 53-55.e7.	1.3	51
52	Collagen proportion area is an independent predictor of longterm outcome in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2017, 66, S52.	3.7	1
53	Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. <i>Journal of Hepatology</i> , 2017, 67, 1265-1273.	3.7	730
54	SAF score and mortality in NAFLD after up to 41 years of follow-up. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 87-91.	1.5	32

#	ARTICLE	IF	CITATIONS
55	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 159-165.	1.5	60
56	Automated quantification of steatosis: agreement with stereological point counting. <i>Diagnostic Pathology</i> , 2017, 12, 80.	2.0	15
57	Natural History of NAFLD/NASH. <i>Current Hepatology Reports</i> , 2017, 16, 391-397.	0.9	102
58	Reply. <i>Hepatology</i> , 2016, 64, 310-311.	7.3	0
59	Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. <i>Liver International</i> , 2016, 36, 1688-1695.	3.9	54
60	Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1126-1132.	1.5	13
61	Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. <i>PLoS ONE</i> , 2016, 11, e0167776.	2.5	17
62	Littoral Cell Angioma in a Patient with Crohn's Disease. <i>Case Reports in Gastrointestinal Medicine</i> , 2015, 2015, 1-4.	0.3	5
63	A Novel SMAD4 Mutation Causing Severe Juvenile Polyposis Syndrome with Protein Losing Enteropathy, Immunodeficiency, and Hereditary Haemorrhagic Telangiectasia. <i>Case Reports in Gastrointestinal Medicine</i> , 2015, 2015, 1-5.	0.3	9
64	Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. <i>Translational Research</i> , 2015, 165, 658-666.	5.0	28
65	Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. <i>Hepatology</i> , 2015, 61, 1547-1554.	7.3	1,683
66	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. <i>PLoS Medicine</i> , 2014, 11, e1001680.	8.4	507
67	Pinworm Infestation Mimicking Crohn's Disease. <i>Case Reports in Gastrointestinal Medicine</i> , 2013, 2013, 1-4.	0.3	6
68	Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 108-115.	1.5	42
69	High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation. <i>Human Immunology</i> , 2012, 73, 382-388.	2.4	25
70	Resistin is Associated with Breach of Tolerance and Anti-nuclear Antibodies in Patients with Hepatobiliary Inflammation. <i>Scandinavian Journal of Immunology</i> , 2011, 74, 463-470.	2.7	13
71	Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 366-374.	1.5	183
72	Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy. <i>European Journal of Radiology</i> , 2008, 66, 313-320.	2.6	39

#	ARTICLE	IF	CITATIONS
73	Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study. <i>Journal of Hepatology</i> , 2007, 47, 135-141.	3.7	242
74	Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 821-830.	3.7	58
75	Long-term follow-up of patients with NAFLD and elevated liver enzymes. <i>Hepatology</i> , 2006, 44, 865-873.	7.3	2,038
76	Letter to the editor. <i>Clinical Transplantation</i> , 2005, 19, 571-571.	1.6	1
77	Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. <i>Modern Pathology</i> , 2005, 18, 912-916.	5.5	100